Table 2.
Patient baseline characteristics of patients treated with ipragliflozin 50 mg or placebo (pooled comparative studies)
| Patient characteristics | Ipragliflozin 50 mg (N = 1209) | Placebo (N = 796) |
|---|---|---|
| Sex, n (%) | ||
| Female | 475 (39.3) | 339 (42.6) |
| Male | 734 (60.7) | 457 (57.4) |
| Race, n (%) | ||
| White | 209 (17.3) | 151 (19.0) |
| Black | 9 (0.7) | 11 (1.4) |
| Asian | 979 (81.0) | 618 (77.6) |
| Other | 12 (1.0) | 16 (2.0) |
| Age (years) | 58.1 (10.3) | 57.4 (9.9) |
| Height (cm) | 163.9 (9.2) | 163.4 (8.9) |
| Weight (kg) | 73.4 (16.1) | 72.9 (15.4) |
| BMI (kg/m2) | 27.2 (4.8) | 27.2 (4.8) |
| BMI, n (%) | ||
| < 25 kg/m2 | 456 (37.7) | 300 (37.7) |
| ≥ 25 kg/m2 | 753 (62.3) | 496 (62.3) |
| Disease duration (months)a | 102.5 (81.9) | 97.5 (79.1) |
| HbA1c (%)b | 8.19 (0.81) | 8.14 (0.82) |
| eGFR (mL/min/1.73 m2)b | 88.8 (29.2) | 93.5 (35.6) |
| eGFR, n (%)b | ||
| > 90 mL/min/1.73 m2 | 483 (40.0) | 360 (45.2) |
| ≥ 60–< 90 mL/min/1.73 m2 | 627 (51.9) | 383 (48.1) |
| ≥ 30–< 60 mL/min/1.73 m2 | 96 (8.0) | 53 (6.7) |
| < 30 mL/min/1.73 m2 | 1 (0.1) | 0 (0) |
Data are mean (SD), unless otherwise indicated, in participants who received at least one dose of study drug
BMI body mass index, HbA1c glycated haemoglobin A1c, eGFR estimated glomerular filtration rate by Modification of Diet in Renal Disease (MDRD) equation
aIpragliflozin, n = 1201; placebo, n = 790
bIpragliflozin, n = 1207; placebo, n = 796